It is essential to highlight the weaknesses of the study,
these having to do with its retrospective nature and
the review of medical records, increasing the chance of
information bias.These results are important in justifying a therapeutic
approach to a payer in light of data on adherence
to methotrexate and the use of Jaki or IL6 blockers as
monotherapyIncluding patients initiating
treatment since 2013 allows us to see a population with
characteristics representing current treatment trends.